# American Shared Hospital Services: overview AMS · NYSE · CIK 744825 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/ams.md) · [Financials](/companies/ams/financials.md) · [Filings](/companies/ams/filings.md) · [Insiders](/companies/ams/insiders.md) Latest reported revenue: [$8.4m](/filings/0001437749-26-027716.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001437749-26-027716). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [6,999](/filings/0001437749-26-001452.md) | [9,069 d](/filings/0001437749-26-010731.md) | [6,112](/filings/0001437749-26-017046.md) | [7,071](/filings/0001437749-26-027716.md) | [7,171](/filings/0001437749-26-001452.md) | [7,728 d](/filings/0001437749-26-010731.md) | [7,084](/filings/0001437749-26-017046.md) | [8,430](/filings/0001437749-26-027716.md) | | Gross margin | % | [19.6%](/filings/0001437749-26-001452.md) | [35.3% d](/filings/0001437749-26-010731.md) | [15.4%](/filings/0001437749-26-017046.md) | [23.1%](/filings/0001437749-26-027716.md) | [22.1%](/filings/0001437749-26-001452.md) | [11.7% d](/filings/0001437749-26-010731.md) | [18.2%](/filings/0001437749-26-017046.md) | [17.0%](/filings/0001437749-26-027716.md) | | Operating margin | % | [(12.7%)](/filings/0001437749-26-001452.md) | [(20.2%) d](/filings/0001437749-26-010731.md) | [(21.3%)](/filings/0001437749-26-017046.md) | [(7.7%)](/filings/0001437749-26-027716.md) | [(4.8%)](/filings/0001437749-26-001452.md) | [(18.1%) d](/filings/0001437749-26-010731.md) | [(13.0%)](/filings/0001437749-26-017046.md) | [(10.8%)](/filings/0001437749-26-027716.md) | | Net margin | % | [(3.0%)](/filings/0001437749-26-001452.md) | [(14.6%) d](/filings/0001437749-26-010731.md) | [(10.2%)](/filings/0001437749-26-017046.md) | [(4.0%)](/filings/0001437749-26-027716.md) | [(0.2%)](/filings/0001437749-26-001452.md) | [(8.2%) d](/filings/0001437749-26-010731.md) | [(8.6%)](/filings/0001437749-26-017046.md) | [(6.1%)](/filings/0001437749-26-027716.md) | | Diluted EPS | $ per share | [(0.03)](/filings/0001437749-26-001452.md) | not reported | [(0.10)](/filings/0001437749-26-017046.md) | [(0.04)](/filings/0001437749-26-027716.md) | [0.00](/filings/0001437749-26-001452.md) | not reported | [(0.09)](/filings/0001437749-26-017046.md) | [(0.07)](/filings/0001437749-26-027716.md) | | Free cash flow | $k | [(407) d](/filings/0001437749-26-001452.md) | [(4,386) d](/filings/0001437749-26-010731.md) | [(1,512)](/filings/0001437749-26-017046.md) | [(2,273) d](/filings/0001437749-26-027716.md) | [(2,031) d](/filings/0001437749-26-001452.md) | [(2,688) d](/filings/0001437749-26-010731.md) | [2,108](/filings/0001437749-26-017046.md) | [2,178 d](/filings/0001437749-26-027716.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [17.6](/filings/0001437749-23-008796.md) | [19.7](/filings/0001437749-24-010308.md) | [21.3](/filings/0001437749-25-011052.md) | [28.3](/filings/0001437749-26-010731.md) | [28.1](/filings/0001437749-26-010731.md) | | Gross margin | % | [38.2%](/filings/0001437749-23-008796.md) | [42.4%](/filings/0001437749-24-010308.md) | [43.8%](/filings/0001437749-25-011052.md) | [32.4%](/filings/0001437749-26-010731.md) | [18.0%](/filings/0001437749-26-010731.md) | | Operating margin | % | [7.7%](/filings/0001437749-23-008796.md) | [12.3%](/filings/0001437749-24-010308.md) | [1.3%](/filings/0001437749-25-011052.md) | [(9.9%)](/filings/0001437749-26-010731.md) | [(12.8%)](/filings/0001437749-26-010731.md) | | Net margin | % | [1.1%](/filings/0001437749-23-008796.md) | [6.7%](/filings/0001437749-24-010308.md) | [2.9%](/filings/0001437749-25-011052.md) | [7.7%](/filings/0001437749-26-010731.md) | [(5.5%)](/filings/0001437749-26-010731.md) | | Diluted EPS | $ per share | [0.03](/filings/0001437749-23-008796.md) | [0.21](/filings/0001437749-24-010308.md) | [0.10](/filings/0001437749-25-011052.md) | [0.33](/filings/0001437749-26-010731.md) | [(0.23)](/filings/0001437749-26-010731.md) | | Free cash flow | $m | [4.6](/filings/0001437749-23-008796.md) | [6.8](/filings/0001437749-24-010308.md) | [(0.6)](/filings/0001437749-25-011052.md) | [(7.8)](/filings/0001437749-26-010731.md) | [(4.5)](/filings/0001437749-26-010731.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ams/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $161.4k | 102,140 | | Reduced −102,980 | | [LPL Financial LLC](/funds/1403438.md) | 2026-06-30 | $128.6k | 81,386 | | Added +5,020 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $91.2k | 57,695 | | Added +8,495 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $87.9k | 55,662 | | Reduced −98,075 | | [JAMES INVESTMENT RESEARCH, INC.](/funds/810384.md) | 2026-06-30 | $47.0k | 29,725 | | Unchanged | | [NewEdge Advisors, LLC](/funds/1633516.md) | 2026-06-30 | $47.0k | 29,725 | | Unchanged | | [BRIDGEWAY CAPITAL MANAGEMENT, LLC](/funds/1107261.md) | 2026-06-30 | $46.0k | 29,124 | | Reduced −61,696 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $41.9k | 26,497 | | Reduced −6,091 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $40.1k | 25,363 | | Reduced −2,043 | | [XTX Topco Ltd](/funds/1828301.md) | 2026-06-30 | $30.2k | 19,107 | | New +19,107 | ## Recent filings [All 524 filings](/companies/ams/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-13 | 16:41 ET | [10-Q](/filings/0001437749-26-027716.md) | Quarterly report, period 2026-06-30 | 0001437749-26-027716 | | 2026-08-13 | 12:44 ET | [8-K](/filings/0001437749-26-027549.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-027549 | | 2026-07-30 | 20:30 ET | [SCHEDULE 13D/A](/filings/0001437749-26-025133.md) | Ownership report, active investor, amended | 0001437749-26-025133 | | 2026-07-28 | 16:21 ET | [8-K](/filings/0001437749-26-024677.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001437749-26-024677 | | 2026-07-13 | 16:16 ET | [8-K](/filings/0001437749-26-023433.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001437749-26-023433 | | 2026-06-30 | 13:34 ET | [8-K](/filings/0001437749-26-022119.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001437749-26-022119 | | 2026-06-25 | 13:25 ET | [SCHEDULE 13D/A](/filings/0001437749-26-021656.md) | Ownership report, active investor, amended | 0001437749-26-021656 | | 2026-06-23 | 11:52 ET | [SCHEDULE 13D/A](/filings/0001185185-26-002614.md) | Ownership report, active investor, amended | 0001185185-26-002614 | | 2026-06-04 | 16:06 ET | [8-K](/filings/0001437749-26-019561.md) | 2.04 Item not in the standard list | 0001437749-26-019561 | | 2026-05-14 | 16:07 ET | [10-Q](/filings/0001437749-26-017046.md) | Quarterly report, period 2026-03-31 | 0001437749-26-017046 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001437749-26-010731.md), filed Mar 31, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/0bf7d732-a734-4b63-989c-41415cd6dd0f) ## About the filer - CIK: 744825 - Tickers: AMS - Exchange: NYSE - SIC code: 8071 Services-Medical Laboratories - State of incorporation: CA - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:23 ET. No prices; not investment advice.